About 90% of the outstanding issues in the debate over promoting ageneric drug market in Mexico have been resolved, it is reported. The full version of the new public health law regulations should be ready in a few weeks.
Government and industry have still to deal with whether doctors will have to prescribe with the generic name as well as the brand name, noted Dagoberto Cortes, pharmaceutical director of Farmaceuticos Lakeside; several legal resources will be kept open. Lack of full agreement on the new law has meant it has not yet come into force, although it has been approved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze